Padeliporfin

Chemical formula: C₃₇H₅₉N₅O₉PdS Molecular mass: 840.26 g/mol

Therapeutic indications

Padeliporfin is indicated for:

Adenocarcinoma of the prostate

Population group: men, only adults (18 years old or older)

Padeliporfin is indicated as monotherapy for adult patients with previously untreated, unilateral, low-risk, adenocarcinoma of the prostate with a life expectancy ≥10 years and:

Clinical stage T1c or T2a,
Gleason Score ≤6, based on high-resolution biopsy strategies,
PSA ≤10 ng/mL,
3 positive cancer cores with a maximum cancer core length of 5 mm in any one core or 1-2 positive cancer cores with ≥50% cancer involvement in any one core or a PSA density ≥0.15 ng/mL/cm³.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

3.66 mg/kg once

Contraindications

Padeliporfin is contraindicated in the following cases:

Cholestasis

Rectal inflammatory bowel disease

Crohn disease of anal canal

Damaged internal urinary sphincter

Urinary incontinence due to urethral sphincter incompetence

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.